Please provide your email address to receive an email when new articles are posted on . Recessive dystrophic epidermolysis bullosa is a rare and serious condition. Zevaskyn is the first FDA-approved ...
CLEVELAND, April 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of NewYork-Presbyterian/Columbia University Irving Medical Center in New York, NY as ...
Please provide your email address to receive an email when new articles are posted on . Krystal Biotech submitted a marketing authorization application to the European Medicines Agency for dystrophic ...
Combining their individual fortés, the laboratories of Dave Holtzman at Washington University, St. Louis, and Brian Bacskai and Brad Hyman at Massachusetts General Hospital, Charlestown, treat us to ...
Credit: Krystal Biotech. Vyjuvek is a topical HSV-1 vector-based gene therapy. The Food and Drug Administration (FDA) has approved Vyjuvek ™ (beremagene geperpavec-svdt) for the treatment of wounds in ...
Company to Host Conference Call Today, March 30, at 4:30pm ETBOCA RATON, Fla., March 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company ...
Recombinant adeno-associated viral vectors (rAAVs) are used for therapeutic gene transfer in skeletal muscle, but it is unclear if immune reactivity to gene transfer and persistence of transgene are ...
Prademagene zamikeracel (Zevaskyn) is the first and only cell-based gene therapy for wound treatment in patients with recessive dystrophic epidermolysis bullosa. The approval is based on the pivotal ...
This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye. In 1999, I defined regenerative medicine as the collection of ...
The deficiencies noted in the CRL were not related to efficacy or safety data. The Food and Drug Administration (FDA) has issued a Complete Response Letter to Abeona Therapeutics regarding the ...
The study, published in Lancet Neurology, detailed the "head-to-head" trial implemented by the researchers to test two drugs, mexiletine and lamotrigine, on people with the condition. The trial, which ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results